FlipGFP Protease Assay for Evaluating In vitro Inhibitory Activity Against SARS-CoV-2 M and PL

Overview

Journal STAR Protoc

Publisher Cell Press

Specialties Biology
Biomedical Engineering
Science

Date 2023 Jun 17

PMID 37329507

Authors

Haozhou Tan

Yanmei Hu

Jun Wang

Affiliations

Soon will be listed here.

Abstract

FlipGFP assay characterizes the intracellular drug target engagement to M and PL and can be performed in the biosafety level 1/2 settings. Here, we provide the detailed protocol for the cell-based FlipGFP assay to identify and characterize SARS-CoV-2 M and PL inhibitors. We describe steps for cell passage and seeding, transfection, addition of compounds, and their incubation and timing. We then detail the quantification of the fluorescence signal of the assay For complete details on the use and execution of this protocol, please refer to Ma et al..

Citing Articles

Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates.

Jadhav P, Liang X, Ansari A, Tan B, Tan H, Li K Nat Commun. 2025; 16(1):1604.

PMID: 39948104 PMC: 11825904. DOI: 10.1038/s41467-025-56902-x.

A Gaussia luciferase reporter assay for the evaluation of coronavirus Nsp5/3CLpro activity.

Vlachou A, Nchioua R, Regensburger K, Kirchhoff F, Kmiec D Sci Rep. 2024; 14(1):20697.

PMID: 39237598 PMC: 11377810. DOI: 10.1038/s41598-024-71305-6.

References

Tan H, Ma C, Wang J . Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor. Med Chem Res. 2022; 31(7):1147-1153. PMC: 9095416. DOI: 10.1007/s00044-022-02903-0. View

Zhou S, Hill C, Sarkar S, Tse L, Woodburn B, Schinazi R . β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis. 2021; 224(3):415-419. PMC: 8136050. DOI: 10.1093/infdis/jiab247. View

Vangeel L, Chiu W, De Jonghe S, Maes P, Slechten B, Raymenants J . Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. 2022; 198:105252. PMC: 8785409. DOI: 10.1016/j.antiviral.2022.105252. View

Li X, Lidsky P, Xiao Y, Wu C, Garcia-Knight M, Yang J . Ethacridine inhibits SARS-CoV-2 by inactivating viral particles. PLoS Pathog. 2021; 17(9):e1009898. PMC: 8445489. DOI: 10.1371/journal.ppat.1009898. View

Joyce R, Hu V, Wang J . The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med Chem Res. 2022; 31(10):1637-1646. PMC: 9425786. DOI: 10.1007/s00044-022-02951-6. View

Ghosh A, Mishevich J, Mesecar A, Mitsuya H . Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19. ChemMedChem. 2022; 17(22):e202200440. PMC: 9538661. DOI: 10.1002/cmdc.202200440. View

Owen D, Allerton C, Anderson A, Aschenbrenner L, Avery M, Berritt S . An oral SARS-CoV-2 M inhibitor clinical candidate for the treatment of COVID-19. Science. 2021; 374(6575):1586-1593. DOI: 10.1126/science.abl4784. View

Tan B, Joyce R, Tan H, Hu Y, Wang J . SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies. Acc Chem Res. 2022; 56(2):157-168. PMC: 9843634. DOI: 10.1021/acs.accounts.2c00735. View

Hu Y, Lewandowski E, Tan H, Zhang X, Morgan R, Zhang X . Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. ACS Cent Sci. 2023; 9(8):1658-1669. PMC: 10451032. DOI: 10.1021/acscentsci.3c00538. View

10.

Froggatt H, Heaton B, Heaton N . Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay. J Virol. 2020; 94(22). PMC: 7592234. DOI: 10.1128/JVI.01265-20. View

11.

Ma C, Xia Z, Sacco M, Hu Y, Townsend J, Meng X . Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity. J Am Chem Soc. 2021; 143(49):20697-20709. PMC: 8672434. DOI: 10.1021/jacs.1c08060. View

12.

Iketani S, Mohri H, Culbertson B, Hong S, Duan Y, Luck M . Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2022; 613(7944):558-564. PMC: 9849135. DOI: 10.1038/s41586-022-05514-2. View

13.

Ma C, Tan H, Choza J, Wang Y, Wang J . Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays. Acta Pharm Sin B. 2021; 12(4):1636-1651. PMC: 8558150. DOI: 10.1016/j.apsb.2021.10.026. View

14.

Vkovski P, Kratzel A, Steiner S, Stalder H, Thiel V . Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2020; 19(3):155-170. PMC: 7592455. DOI: 10.1038/s41579-020-00468-6. View

15.

Zhang Q, Schepis A, Huang H, Yang J, Ma W, Torra J . Designing a Green Fluorogenic Protease Reporter by Flipping a Beta Strand of GFP for Imaging Apoptosis in Animals. J Am Chem Soc. 2019; 141(11):4526-4530. PMC: 6486793. DOI: 10.1021/jacs.8b13042. View

16.

Araf Y, Akter F, Tang Y, Fatemi R, Parvez M, Zheng C . Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022; 94(5):1825-1832. PMC: 9015557. DOI: 10.1002/jmv.27588. View

17.

Ma C, Sacco M, Xia Z, Lambrinidis G, Townsend J, Hu Y . Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay. ACS Cent Sci. 2021; 7(7):1245-1260. PMC: 8265724. DOI: 10.1021/acscentsci.1c00519. View

18.

Barouch D . Covid-19 Vaccines - Immunity, Variants, Boosters. N Engl J Med. 2022; 387(11):1011-1020. PMC: 9454645. DOI: 10.1056/NEJMra2206573. View

19.

Xia Z, Sacco M, Hu Y, Ma C, Meng X, Zhang F . Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir. ACS Pharmacol Transl Sci. 2021; 4(4):1408-1421. PMC: 8204911. DOI: 10.1021/acsptsci.1c00099. View

20.

Ma C, Hu Y, Wang Y, Choza J, Wang J . Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor. ACS Infect Dis. 2022; 8(5):1022-1030. PMC: 9017246. DOI: 10.1021/acsinfecdis.1c00629. View